JP2016520074A - Cd19特異的キメラ抗原受容体およびその使用 - Google Patents
Cd19特異的キメラ抗原受容体およびその使用 Download PDFInfo
- Publication number
- JP2016520074A JP2016520074A JP2016513321A JP2016513321A JP2016520074A JP 2016520074 A JP2016520074 A JP 2016520074A JP 2016513321 A JP2016513321 A JP 2016513321A JP 2016513321 A JP2016513321 A JP 2016513321A JP 2016520074 A JP2016520074 A JP 2016520074A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- antigen receptor
- chimeric antigen
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 title claims 14
- 210000004027 cell Anatomy 0.000 claims abstract description 193
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 75
- 210000002865 immune cell Anatomy 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 38
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 37
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 37
- 239000002157 polynucleotide Substances 0.000 claims abstract description 37
- 108020001756 ligand binding domains Proteins 0.000 claims abstract description 27
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 24
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 24
- 208000004736 B-Cell Leukemia Diseases 0.000 claims abstract description 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 230000011664 signaling Effects 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 230000004068 intracellular signaling Effects 0.000 claims description 7
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 108010083359 Antigen Receptors Proteins 0.000 claims description 3
- 102000006306 Antigen Receptors Human genes 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 53
- 239000003446 ligand Substances 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 21
- 230000027455 binding Effects 0.000 abstract description 18
- 230000007774 longterm Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000009257 reactivity Effects 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 68
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 230000000139 costimulatory effect Effects 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 229920001184 polypeptide Polymers 0.000 description 25
- 108010042407 Endonucleases Proteins 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 23
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 101710163270 Nuclease Proteins 0.000 description 19
- 230000004913 activation Effects 0.000 description 18
- 102000053602 DNA Human genes 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 102100031780 Endonuclease Human genes 0.000 description 15
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 15
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 14
- 241000700605 Viruses Species 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000010361 transduction Methods 0.000 description 12
- 230000026683 transduction Effects 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- -1 OX-40 (CD134) Proteins 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 102000004533 Endonucleases Human genes 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 8
- 108091033409 CRISPR Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000007420 reactivation Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 102100038078 CD276 antigen Human genes 0.000 description 5
- 101710185679 CD276 antigen Proteins 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 5
- 102100035793 CD83 antigen Human genes 0.000 description 5
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102100027207 CD27 antigen Human genes 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 description 3
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000005931 immune cell recruitment Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 102000002627 4-1BB Ligand Human genes 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
- 108010024164 HLA-G Antigens Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 2
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 2
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 2
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108020003285 Isocitrate lyase Proteins 0.000 description 2
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 2
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 2
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 2
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 2
- 102000004473 OX40 Ligand Human genes 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000006420 basal activation Effects 0.000 description 2
- 230000008275 binding mechanism Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940112129 campath Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000017455 cell-cell adhesion Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 102000052907 GIY-YIG endonucleases Human genes 0.000 description 1
- 108700035841 GIY-YIG endonucleases Proteins 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 108050008753 HNH endonucleases Proteins 0.000 description 1
- 102000000310 HNH endonucleases Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000746783 Homo sapiens Cytochrome b-c1 complex subunit 6, mitochondrial Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100026215 Immunoglobulin gamma-1 heavy chain Human genes 0.000 description 1
- 101710111858 Immunoglobulin gamma-1 heavy chain Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000011347 external beam therapy Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000048638 human UQCRH Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Description
本発明は、キメラ抗原受容体(CAR)に関する。CARは、リガンド結合ドメイン特性を活用して、免疫細胞の特異性および反応性を選択された標的へ向け直すことができる。具体的には、本発明は、細胞外リガンド結合が、CD19モノクローナル抗体、好ましくは、4G7に由来するscFVであるキメラ抗原受容体に関する。本発明は、CARをコードするポリヌクレオチド、ベクター、およびCARを表面に発現する単離された細胞にも関する。本発明は、形質導入された細胞により長期間の「活性化」状態を付与する4G7-CARを表面に発現するように免疫細胞を操作する方法にも関する。本発明は、B細胞リンパ腫およびB細胞白血病の処置のために特に有用である。
エクスビボで生成された自己の抗原特異的T細胞の移入を含む養子免疫治療は、ウイルス感染および癌を処置するための有望な戦略である。養子免疫治療のために使用されるT細胞は、抗原特異的T細胞の増大または遺伝子操作を通したT細胞の向け直しのいずれかによって生成され得る(Park,Rosenberg et al.2011)。ウイルス抗原特異的T細胞の移入は、移植に関連したウイルス感染および稀なウイルス関連悪性疾患の処置のために使用されている、よく確立された手法である。同様に、腫瘍特異的T細胞の単離および移入は、黒色腫の処置において成功が示されている。
本明細書において特に定義されない限り、使用される技術用語および科学用語は、全て、遺伝子治療、生化学、遺伝学、および分子生物学の領域の当業者によって一般的に理解されるのと同一の意味を有する。
本発明は、細胞外リガンド結合ドメイン、膜貫通ドメイン、およびシグナリング伝達ドメインを含むキメラ抗原受容体(CAR)に関する。
本発明は、上記の本発明によるCARをコードするポリヌクレオチド、ベクターにも関する。好ましい態様において、本発明は、核酸配列SEQ ID NO:17を含むポリヌクレオチドに関する。好ましい態様において、ポリヌクレオチドは、SEQ ID NO:17からなる群より選択される核酸配列との少なくとも70%、好ましくは、少なくとも80%、より好ましくは、少なくとも90%、95%、97%、または99%の配列同一性を有する。
包含される具体的な態様において、本発明は、本発明によるCARを免疫細胞へ導入する工程、および該細胞を増大させる工程を含む、免疫治療のための免疫細胞を調製する方法に関する。具体的な態様において、本発明は、細胞を準備する工程、および該細胞の表面に少なくとも1種の上記のCARを発現させる工程を含む、免疫細胞を操作する方法に関する。具体的な態様において、方法は、上記のCARをコードする少なくとも1種のポリヌクレオチドによって細胞を形質転換する工程、およびポリヌクレオチドを細胞において発現させる工程を含む。
上記の異なる方法は、CARを細胞へ導入する工程を含む。非限定的な例として、CARは、1種のプラスミドベクターによってコードされたトランスジーンとして導入され得る。プラスミドベクターは、ベクターを受容した細胞の同定および/または選択を提供する選択マーカーも含有し得る。
本発明は、細胞を操作する方法によって入手可能な単離された細胞または細胞株にも関する。具体的には、単離された細胞は、少なくとも1種の上記のCARを含む。別の態様において、単離された細胞は、各々異なる細胞外リガンド結合ドメインを含むCARの集団を含む。具体的には、単離された細胞は、CARをコードする外因性のポリヌクレオチド配列を含む。本発明の遺伝子改変免疫細胞は、活性化されており、抗原結合機序と無関係に増殖する。
本発明の遺伝子改変免疫細胞は、活性化されており、抗原結合機序と無関係に増殖するが、本発明の免疫細胞、具体的には、T細胞は、T細胞の遺伝子改変の前であっても後であっても、例えば、米国特許第6,352,694号;第6,534,055号;第6,905,680号;第6,692,964号;第5,858,358号;第6,887,466号;第6,905,681号;第7,144,575号;第7,067,318号;第7,172,869号;第7,232,566号;第7,175,843号;第5,883,223号;第6,905,874号;第6,797,514号;第6,867,041号;および米国特許出願公開第20060121005号に記載されるような方法を一般に使用して、さらに活性化させ増大させることができる。T細胞は、インビトロまたはインビボで増大させることができる。
別の態様において、既に記載されたような異なる方法によって入手された単離された細胞または単離された細胞に由来する細胞株は、医薬として使用され得る。別の態様において、医薬は、その必要のある患者において、癌を処置するため、具体的には、B細胞リンパ腫およびB細胞白血病の処置のため、使用され得る。別の態様において、本発明による単離された細胞または単離された細胞に由来する細胞株は、その必要のある患者における癌の処置のための医薬の製造において使用され得る。
(a)既に記載された方法のいずれかによって入手可能な免疫細胞を準備する工程;
(b)形質転換された免疫細胞を患者へ投与する工程。
他に特記されない限り、「a」、「an」、「the」、および「少なくとも1」は、交換可能に使用され、1または複数を意味する。ポリペプチド配列内のアミノ酸残基は、1文字コードによって本明細書において表記され、例えば、QはGln、すなわちグルタミン残基を意味し、RはArg、すなわちアルギニン残基を意味し、DはAsp、すなわちアスパラギン酸残基を意味する。
T細胞受容体α定常鎖領域(TRAC)遺伝子内の15bpスペーサーによって隔てられた2個の17bp長配列(半標的と呼ぶ)を標的とする異種二量体TALEヌクレアーゼを設計し作製した。半標的は、各々、表1にリストされた半TALEヌクレアーゼのリピートによって認識される。
4G7 scFVが、形質導入された細胞により長期間の「活性化」状態を付与するか否かを決定するため、4G7 scFV(SEQ ID NO:17によってコードされたSEQ ID NO:15)または古典的なFMC63 scFV(SEQ ID NO:16)を保有するCARによって形質導入されたT細胞の基底活性化を比較した。精製されたヒトT細胞を、以下のプロトコルに従って形質導入した:簡単に説明すると、抗CD3/CD28によってコーティングされたビーズおよび組換えIL2によって3日間予備活性化された1×106個のCD3+細胞を、30μg/mlレトロネクチン(retronectin)によってコーティングされた12穴非組織培養プレートにおいて、5のMOIで4G7-CAR(SEQ ID NO:15)およびFMC63-CAR(SEQ ID NO:16)をコードするレンチウイルスベクターによって形質導入した。形質導入の24時間後、培地を除去し、新鮮な培地に交換した。次いで、2〜3日毎に細胞数を測定することによって、培養期間を通じて、1×106細胞/mlの濃度に細胞を維持した。4G7-CARまたはFMC63-CARのいずれかをコードするレンチウイルスベクターによる形質導入の3日後、8日後、および15日後に、CAR発現細胞の百分率をフローサイトメトリーによって査定した。2種のレンチウイルスベクターで、形質導入の効率が比較的等しいことが観察された(図3)。
4G7 scFVがより高い増殖活性を付与するか否かを決定するため、4G7 scFV(SEO ID NO:17によってコードされたSEO ID NO:15)または古典的なFMC63 scFV(SEO ID NO:16)を保有するCARによって形質導入されたT細胞の増殖を、1週間に2回、細胞を計数することによって20日まで追跡した。精製されたヒトT細胞を、以下のプロトコルによって形質導入した:簡単に説明すると、抗CD3/CD28によってコーティングされたビーズおよび組換えIL2によって3日間予備活性化された1×106個のCD3+細胞を、4G7-CAR(SEO ID NO:15)およびFMC63-CAR(SEO ID NO:16)をコードするレンチウイルスベクターによって形質導入した。次いで、細胞を古典的な条件の下で維持し、12日目に再活性化した。細胞を同一の密度で播種し、20日間、1週間に2回、計数した。図6に表されるように、4G7-CARを発現するT細胞の増殖活性は、古典的なFMC63-CARを発現する細胞のものと比較して2倍高い。
Claims (22)
- 少なくとも1つの細胞外リガンド結合ドメイン、膜貫通ドメイン、および少なくとも1つの細胞内シグナリングドメインを含むCD19特異的キメラ抗原受容体であって、該細胞外ドメインが、CD19に特異的なモノクローナル抗体4G7のγ重鎖(SEQ ID NO:1)およびκ軽鎖(SEQ ID NO:2)に由来する単鎖FV断片を含む、CD19特異的キメラ抗原受容体。
- モノクローナル抗体4G7に由来する単鎖FV断片が、SEQ ID NO:3〜5およびSEQ ID NO:7〜8からなる群より選択されるアミノ酸配列を含む、請求項1記載のCD19特異的キメラ抗原受容体。
- 細胞内シグナリングドメインがCD3ζシグナリングドメインを含む、請求項1または2記載のCD19特異的キメラ抗原受容体。
- 細胞内シグナリングドメインが4-1BBドメインを含む、請求項1〜3のいずれか一項記載のCD19特異的キメラ抗原受容体。
- ヒトCD8α鎖の膜貫通ドメインおよびストークドメインを含む、請求項1〜4のいずれか一項記載のCD19特異的キメラ抗原受容体。
- アミノ酸配列SEQ ID NO:14および15と少なくとも75%、好ましくは80%、85%、90%、95%を有するアミノ酸配列を含む、請求項1〜5のいずれか一項記載のCD19特異的キメラ抗原受容体。
- CD19に特異的ではない他の細胞外リガンド結合ドメインをさらに含む、請求項1〜6のいずれか一項記載のCD19特異的キメラ抗原受容体。
- 請求項1〜7のいずれか一項記載のキメラ抗原受容体をコードするポリヌクレオチド。
- アミノ酸配列SEQ ID NO:17と少なくとも75%、好ましくは80%、85%、90%、95%を有する核酸配列を含む、請求項8記載のポリヌクレオチド。
- 請求項8または9記載の核酸を含む発現ベクター。
- 少なくとも1つの細胞外リガンド結合ドメインおよび少なくとも1つの細胞内シグナリングドメインを含むCD19特異的キメラ抗原受容体を細胞表面膜に発現する遺伝子操作免疫細胞であって、細胞外ドメインが、CD19に特異的なモノクローナル抗体4G7に由来する単鎖FV断片を含む、遺伝子操作免疫細胞。
- 請求項1〜7のいずれか一項記載のCD19特異的キメラ抗原受容体を細胞表面膜に発現する遺伝子操作免疫細胞。
- CD19に特異的ではない他のキメラ抗原受容体をさらに含む、請求項11または12記載の遺伝子操作免疫細胞。
- 炎症性Tリンパ球、細胞傷害性Tリンパ球、制御性Tリンパ球、またはヘルパーTリンパ球に由来する、請求項11〜13のいずれか一項記載の遺伝子操作免疫細胞。
- ドナーから回収された遺伝子操作免疫細胞。
- 患者から回収された遺伝子操作免疫細胞。
- 治療において使用するための遺伝子操作細胞。
- B細胞リンパ腫およびB細胞白血病において使用するための遺伝子操作細胞。
- (a)免疫細胞を準備する工程、
(b)請求項1〜7のいずれか一項記載の少なくとも1種のCD19特異的キメラ抗原受容体を該細胞の表面に発現させる工程
を含む、免疫細胞を操作する方法。 - (a)免疫細胞を準備する工程、
(b)CD19特異的キメラ抗原受容体をコードする少なくとも1種のポリヌクレオチドを該細胞へ導入する工程、
(c)該ポリヌクレオチドを該細胞において発現させる工程
を含む、請求項19記載の免疫細胞を操作する方法。 - (a)免疫細胞を準備する工程、
(b)CD19特異的キメラ抗原受容体をコードする少なくとも1種のポリヌクレオチドを該細胞へ導入する工程、
(c)CD19に特異的ではない少なくとも1種の他のキメラ抗原受容体を導入する工程
を含む、請求項19記載の免疫細胞を操作する方法。 - (a)請求項1〜7のいずれか一項記載のCD19特異的キメラ抗原受容体を表面に発現している免疫細胞を準備する工程、
(b)該免疫細胞を患者へ投与する工程
を含む、その必要のある対象を処置する方法。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USPCT/US2013/040755 | 2013-05-13 | ||
US13/892,805 | 2013-05-13 | ||
PCT/US2013/040755 WO2013176915A1 (en) | 2012-05-25 | 2013-05-13 | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
PCT/US2013/040766 WO2013176916A1 (en) | 2012-05-25 | 2013-05-13 | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
USPCT/US2013/040766 | 2013-05-13 | ||
US13/892,805 US11603539B2 (en) | 2012-05-25 | 2013-05-13 | Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy |
US201361888259P | 2013-10-08 | 2013-10-08 | |
US61/888,259 | 2013-10-08 | ||
PCT/EP2014/059662 WO2014184143A1 (en) | 2013-05-13 | 2014-05-12 | Cd19 specific chimeric antigen receptor and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019037174A Division JP6854307B2 (ja) | 2013-05-13 | 2019-03-01 | Cd19特異的キメラ抗原受容体およびその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016520074A true JP2016520074A (ja) | 2016-07-11 |
JP2016520074A5 JP2016520074A5 (ja) | 2017-06-08 |
JP6491643B2 JP6491643B2 (ja) | 2019-04-03 |
Family
ID=51897790
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016513321A Active JP6491643B2 (ja) | 2013-05-13 | 2014-05-12 | Cd19特異的キメラ抗原受容体およびその使用 |
JP2019037174A Active JP6854307B2 (ja) | 2013-05-13 | 2019-03-01 | Cd19特異的キメラ抗原受容体およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019037174A Active JP6854307B2 (ja) | 2013-05-13 | 2019-03-01 | Cd19特異的キメラ抗原受容体およびその使用 |
Country Status (30)
Country | Link |
---|---|
US (1) | US20210000869A9 (ja) |
EP (3) | EP3546572B1 (ja) |
JP (2) | JP6491643B2 (ja) |
KR (1) | KR102248157B1 (ja) |
CN (2) | CN105431532B (ja) |
AU (2) | AU2014267436B2 (ja) |
BR (1) | BR112015028387B1 (ja) |
CA (1) | CA2911292C (ja) |
DK (1) | DK3546572T3 (ja) |
EA (2) | EA201990575A3 (ja) |
ES (1) | ES2930431T3 (ja) |
FI (2) | FI3546572T3 (ja) |
HK (2) | HK1222678A1 (ja) |
HR (1) | HRP20221393T1 (ja) |
HU (1) | HUE060901T2 (ja) |
LT (1) | LT2997141T (ja) |
MA (1) | MA38630B2 (ja) |
MX (1) | MX2015015662A (ja) |
MY (1) | MY172897A (ja) |
PH (1) | PH12015502479B1 (ja) |
PL (1) | PL2997141T3 (ja) |
PT (1) | PT2997141T (ja) |
RS (1) | RS63798B1 (ja) |
RU (1) | RU2727447C2 (ja) |
SA (1) | SA515370135B1 (ja) |
SG (2) | SG10201708896WA (ja) |
SI (1) | SI2997141T1 (ja) |
TW (1) | TWI636992B (ja) |
UA (1) | UA118106C2 (ja) |
WO (1) | WO2014184143A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019524100A (ja) * | 2016-07-18 | 2019-09-05 | へリックス バイオファーマ コーポレーション | がんを治療するための癌胎児性抗原関連細胞接着分子6を標的とするcar免疫細胞 |
JP2021501217A (ja) * | 2017-10-31 | 2021-01-14 | アロジーン セラピューティクス,インコーポレイテッド | 同種キメラ抗原受容体t細胞投与のための方法および組成物 |
JP2021505137A (ja) * | 2017-12-06 | 2021-02-18 | アブクロン・インコーポレイテッドAbclon Inc. | 悪性b細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途 |
JP2021516996A (ja) * | 2015-09-11 | 2021-07-15 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生物学的に関連する直交サイトカイン/受容体対 |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
PL2855667T3 (pl) | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
US11077144B2 (en) | 2013-05-13 | 2021-08-03 | Cellectis | CD19 specific chimeric antigen receptor and uses thereof |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
LT3066201T (lt) | 2013-11-07 | 2018-08-10 | Editas Medicine, Inc. | Su crispr susiję būdai ir kompozicijos su valdančiomis grnr |
US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
JP2017504601A (ja) * | 2013-12-20 | 2017-02-09 | セレクティスCellectis | 免疫療法のためにマルチインプットシグナル感受性t細胞を操作する方法 |
US10189908B2 (en) | 2014-02-05 | 2019-01-29 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
JP2017533729A (ja) * | 2014-10-24 | 2017-11-16 | ベーセーエルテー ホールディングス ベーフェー | T細胞ベースの免疫療法薬 |
US20170296623A1 (en) * | 2014-12-17 | 2017-10-19 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
WO2016123143A1 (en) | 2015-01-26 | 2016-08-04 | The University Of Chicago | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2 |
BR112017015453A2 (pt) | 2015-01-26 | 2018-01-23 | Cellectis | células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides |
EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
CN114230670A (zh) * | 2015-02-27 | 2022-03-25 | 美商生物细胞基因治疗有限公司 | 靶向血液恶性肿瘤之嵌合抗原受体(car)、其组合物及使用方法 |
GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
CN107980046B (zh) | 2015-04-13 | 2021-12-24 | 辉瑞公司 | 靶向b细胞成熟抗原的嵌合抗原受体 |
GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN104829733B (zh) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
CN107849112B (zh) | 2015-06-25 | 2022-04-01 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法 |
CA2994746A1 (en) | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
MX2018003533A (es) | 2015-09-24 | 2019-04-25 | Abvitro Llc | Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso. |
WO2017070633A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Evolved cas9 proteins for gene editing |
CA3003144A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
WO2017075537A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
GB201519900D0 (en) * | 2015-11-11 | 2015-12-23 | Ucl Business Plc | Chimeric antigen receptor |
BR112018014585A2 (pt) | 2016-01-21 | 2018-12-11 | Pfizer | receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii |
CN107298715B (zh) * | 2016-04-15 | 2021-05-04 | 阿思科力(苏州)生物科技有限公司 | Slit2D2-嵌合抗原受体及其应用 |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
CN109503721B (zh) * | 2016-05-31 | 2023-03-07 | 上海恒润达生生物科技股份有限公司 | 靶向cd19的嵌合抗原受体及其用途 |
CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
US11242376B2 (en) | 2016-08-02 | 2022-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN109789164B (zh) * | 2016-08-30 | 2023-04-28 | 亘喜生物科技(上海)有限公司 | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 |
KR20190046854A (ko) | 2016-09-14 | 2019-05-07 | 얀센 바이오테크 인코포레이티드 | Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도 |
WO2018058432A1 (zh) * | 2016-09-28 | 2018-04-05 | 李华顺 | 一种多基因重组嵌合抗原受体分子及其应用 |
ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
EP3525804A4 (en) * | 2016-10-11 | 2020-09-09 | Minerva Biotechnologies Corporation | HUMANIZED ANTI-MUC1 * ANTIBODIES AND USE OF THE CLIVING ENZYME |
CA3039928A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
US11767512B2 (en) | 2017-04-13 | 2023-09-26 | Cellectis | Sequence specific reagents targeting CCR5 in primary hematopoietic cells |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
AU2018278321A1 (en) | 2017-06-02 | 2019-11-21 | Pfizer Inc. | Chimeric antigen receptors targeting FLT3 |
EP3645036A1 (en) | 2017-06-30 | 2020-05-06 | Cellectis | Cellular immunotherapy for repetitive administration |
US11161897B2 (en) | 2017-07-17 | 2021-11-02 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type III domains and methods of using the same |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
EP3703689A1 (en) | 2017-11-01 | 2020-09-09 | Allogene Therapeutics, Inc. | Modified caspase-9 polypeptides and methods of use thereof |
WO2019106163A1 (en) | 2017-12-01 | 2019-06-06 | Cellectis | Reprogramming of genetically engineered primary immune cells |
EP3728330A4 (en) * | 2017-12-23 | 2021-12-08 | Uwell Biopharma Inc. | PHARMACEUTICAL COMPOSITION OF CHEMICAL RECEPTOR AND ASSOCIATED PROCESS |
AU2019216420A1 (en) | 2018-02-01 | 2020-08-20 | Pfizer Inc. | Chimeric antigen receptors targeting CD70 |
WO2019152705A1 (en) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Antibodies specific for cd70 and their uses |
PE20201342A1 (es) | 2018-02-28 | 2020-11-25 | Pfizer | Variantes de il-15 y usos de las mismas |
EP3820901A1 (en) * | 2018-07-09 | 2021-05-19 | Oslo Universitetssykehus HF | Two chimeric antigen receptors specifically binding cd19 and igkappa |
EP3887507A1 (en) | 2018-11-30 | 2021-10-06 | Janssen Biotech, Inc. | Gamma delta t cells and uses thereof |
RU2742000C2 (ru) * | 2019-03-13 | 2021-02-01 | Общество С Ограниченной Ответственностью "Анабион" | Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор |
AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
KR20220002888A (ko) | 2019-04-19 | 2022-01-07 | 알로젠 테라퓨틱스 인코포레이티드 | 4g7-유래 키메라 항원 수용체에 대한 항체 |
KR20220004076A (ko) | 2019-04-26 | 2022-01-11 | 알로젠 테라퓨틱스 인코포레이티드 | 리툭시맙-내성 키메라 항원 수용체 및 이의 용도 |
BR112022003471A2 (pt) | 2019-08-27 | 2022-05-24 | Janssen Biotech Inc | Sistema receptor de antígeno quimérico e usos do mesmo |
CN112079934B (zh) * | 2019-12-17 | 2021-01-29 | 合源生物科技(天津)有限公司 | 一种靶向cd19的嵌合抗原受体及其用途 |
MX2022010824A (es) | 2020-03-03 | 2022-11-30 | Janssen Biotech Inc | Células t ¿¿ y usos de estas. |
MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
KR20230019843A (ko) | 2020-05-08 | 2023-02-09 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물 |
US20220023346A1 (en) | 2020-07-21 | 2022-01-27 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
US20220031751A1 (en) | 2020-08-03 | 2022-02-03 | Kyverna Therapeutics, Inc. | Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same |
US20230321239A1 (en) | 2020-08-14 | 2023-10-12 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptor t cells for treating autoimmunity |
CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
WO2022234158A1 (es) * | 2021-05-06 | 2022-11-10 | Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) | Terapia de células t con receptor de antígeno quimérico específico de cd19 |
WO2022266075A1 (en) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080131415A1 (en) * | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
WO2012129514A1 (en) * | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2002077029A2 (en) * | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
EP2059536B1 (en) * | 2006-08-14 | 2014-01-08 | Xencor, Inc. | Optimized antibodies that target cd19 |
PT2211904T (pt) * | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
WO2012050374A2 (en) * | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
JP5947311B2 (ja) * | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変t細胞の使用 |
US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
US20120245996A1 (en) | 2011-03-22 | 2012-09-27 | Jonathan Mendez | System and method for intent-based content matching |
ES2728436T3 (es) | 2011-04-05 | 2019-10-24 | Cellectis | Método para la generación de TALE-nucleasas compactas y usos de la mismas |
US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
AU2012290342A1 (en) * | 2011-07-29 | 2014-01-30 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
US10421960B2 (en) * | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
-
2014
- 2014-05-12 AU AU2014267436A patent/AU2014267436B2/en active Active
- 2014-05-12 MA MA38630A patent/MA38630B2/fr unknown
- 2014-05-12 WO PCT/EP2014/059662 patent/WO2014184143A1/en active Application Filing
- 2014-05-12 PT PT147234363T patent/PT2997141T/pt unknown
- 2014-05-12 FI FIEP19161861.0T patent/FI3546572T3/fi active
- 2014-05-12 SG SG10201708896WA patent/SG10201708896WA/en unknown
- 2014-05-12 EP EP19161861.0A patent/EP3546572B1/en active Active
- 2014-05-12 EA EA201990575A patent/EA201990575A3/ru unknown
- 2014-05-12 MX MX2015015662A patent/MX2015015662A/es active IP Right Grant
- 2014-05-12 KR KR1020157035319A patent/KR102248157B1/ko active IP Right Grant
- 2014-05-12 EP EP14723436.3A patent/EP2997141B1/en active Active
- 2014-05-12 ES ES14723436T patent/ES2930431T3/es active Active
- 2014-05-12 RS RS20221084A patent/RS63798B1/sr unknown
- 2014-05-12 SG SG11201508805UA patent/SG11201508805UA/en unknown
- 2014-05-12 LT LTEPPCT/EP2014/059662T patent/LT2997141T/lt unknown
- 2014-05-12 RU RU2015153250A patent/RU2727447C2/ru active
- 2014-05-12 EA EA201501109A patent/EA036200B1/ru unknown
- 2014-05-12 FI FIEP14723436.3T patent/FI2997141T3/fi active
- 2014-05-12 CN CN201480027071.9A patent/CN105431532B/zh active Active
- 2014-05-12 EP EP24163057.3A patent/EP4364809A2/en active Pending
- 2014-05-12 MY MYPI2015703966A patent/MY172897A/en unknown
- 2014-05-12 SI SI201431999T patent/SI2997141T1/sl unknown
- 2014-05-12 HR HRP20221393TT patent/HRP20221393T1/hr unknown
- 2014-05-12 PL PL14723436.3T patent/PL2997141T3/pl unknown
- 2014-05-12 BR BR112015028387-0A patent/BR112015028387B1/pt active IP Right Grant
- 2014-05-12 JP JP2016513321A patent/JP6491643B2/ja active Active
- 2014-05-12 CN CN201910222072.3A patent/CN109897100A/zh active Pending
- 2014-05-12 HU HUE14723436A patent/HUE060901T2/hu unknown
- 2014-05-12 DK DK19161861.0T patent/DK3546572T3/da active
- 2014-05-12 TW TW103116744A patent/TWI636992B/zh active
- 2014-05-12 CA CA2911292A patent/CA2911292C/en active Active
- 2014-12-05 UA UAA201512065A patent/UA118106C2/uk unknown
-
2015
- 2015-10-27 PH PH12015502479A patent/PH12015502479B1/en unknown
- 2015-11-12 SA SA515370135A patent/SA515370135B1/ar unknown
-
2016
- 2016-09-13 HK HK16110821.6A patent/HK1222678A1/zh unknown
- 2016-09-13 HK HK16110847.6A patent/HK1222679A1/zh unknown
-
2019
- 2019-03-01 JP JP2019037174A patent/JP6854307B2/ja active Active
- 2019-03-15 AU AU2019201818A patent/AU2019201818B2/en active Active
- 2019-03-26 US US16/365,588 patent/US20210000869A9/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080131415A1 (en) * | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
WO2012129514A1 (en) * | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
Non-Patent Citations (4)
Title |
---|
KEBRIAEI, P. ET AL., HUMAN GENE THERAPY, vol. 23, no. 5, JPN5016005673, 1 May 2012 (2012-05-01), pages 444 - 450, ISSN: 0003762078 * |
KEBRIAEI, P. ET AL.: ""CARS: DRIVING T-CELL SPECIFICITY TO ENHANCE ANTI-TUMOR IMMUNITY."", FRONTIERS IN BIOSCIENCE(SCHOLAR EDITION) [ONLINE], vol. 4, JPN5016005672, 1 January 2012 (2012-01-01), pages 520 - 531, ISSN: 0003762077 * |
LIPOWSKA-BHALLA, G. ET AL., CANCER IMMUNOLOGY IMMUNOTHARAPY, vol. 61, no. 7, JPN5016005671, 22 April 2012 (2012-04-22), pages 953 - 962, ISSN: 0003762076 * |
PEIPP, M. ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 285, no. 2, JPN5016005674, 15 February 2004 (2004-02-15), pages 265 - 280, ISSN: 0003762079 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021516996A (ja) * | 2015-09-11 | 2021-07-15 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生物学的に関連する直交サイトカイン/受容体対 |
JP2019524100A (ja) * | 2016-07-18 | 2019-09-05 | へリックス バイオファーマ コーポレーション | がんを治療するための癌胎児性抗原関連細胞接着分子6を標的とするcar免疫細胞 |
US11242386B2 (en) | 2016-07-18 | 2022-02-08 | Helix Biopharma Corp. | CEACAM6 CAR immune cells to treat cancers |
JP7178568B2 (ja) | 2016-07-18 | 2022-11-28 | ナショナル リサーチ カウンシル オブ カナダ | がんを治療するための癌胎児性抗原関連細胞接着分子6を標的とするcar免疫細胞 |
JP2021501217A (ja) * | 2017-10-31 | 2021-01-14 | アロジーン セラピューティクス,インコーポレイテッド | 同種キメラ抗原受容体t細胞投与のための方法および組成物 |
JP7451410B2 (ja) | 2017-10-31 | 2024-03-18 | アロジーン セラピューティクス,インコーポレイテッド | 同種キメラ抗原受容体t細胞投与のための方法および組成物 |
JP2021505137A (ja) * | 2017-12-06 | 2021-02-18 | アブクロン・インコーポレイテッドAbclon Inc. | 悪性b細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途 |
JP7089806B2 (ja) | 2017-12-06 | 2022-06-23 | アブクロン・インコーポレイテッド | 悪性b細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途 |
US11534462B2 (en) | 2017-12-06 | 2022-12-27 | Abclon Inc. | Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6854307B2 (ja) | Cd19特異的キメラ抗原受容体およびその使用 | |
US11007224B2 (en) | CD19 specific chimeric antigen receptor and uses thereof | |
JP7222954B2 (ja) | 癌免疫療法のための栄養膜糖タンパク質(5t4、tpbg)特異的キメラ抗原受容体 | |
JP6673848B2 (ja) | 癌免疫療法のためのcd33特異的キメラ抗原受容体 | |
AU2015245469B2 (en) | Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment | |
US11077144B2 (en) | CD19 specific chimeric antigen receptor and uses thereof | |
NZ714044B2 (en) | Cd19 specific chimeric antigen receptor and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170421 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180907 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190301 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6491643 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |